HCW Biologics Secures $4.0 Million Through Warrant Inducement, Enters Nasdaq Priced At-the-Market Transaction

HCW Biologics has entered into a warrant inducement agreement with an investor to exercise outstanding warrants for $4 million. The warrants had an original exercise price of $2.66, and the investor has agreed to a reduced exercise price of $2.66. The gross proceeds from the exercise are expected to be approximately $4 million. In consideration for the immediate exercise, the Company will issue unregistered warrants to purchase an aggregate of 3,020,410 shares of its common stock.